Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.14 0.31 −4.16%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
700.70 1,067.30 1,280.20 1,240.20 1,552.50 703.10 290.88 195.68 65.53 37.28
Total non-current assets
17.20 24.10 24.40 28.60 29.10 14.30 10.76 3.60 1.32 0.65
Total Assets
717.90 1,091.40 1,304.60 1,268.80 1,581.60 717.40 301.64 199.28 66.85 37.94
Total current liabilities
142.50 229.80 257.10 295.10 261.70 49.20 32.81 22.98 17.85 10.03
Total non-current liabilities
141.50 299.90 387.50 408.80 538.20 26.00 42.14 39.63 48.75 3.87
Total liabilities
284.00 529.70 644.60 703.90 799.90 75.20 74.96 62.61 66.60 13.91
Common Equity (Total)
433.90 561.70 660.00 564.90 781.70 642.20 226.69 136.67 (61.23) (32.88)
Shareholders Equity (Total)
433.90 561.70 660.00 564.90 781.70 642.20 226.69 136.67 0.25 24.03
Total Debt
0.40 0.60 0.80 1.00 1.00 2.00 2.00 2.15 0.31 0.45

Show all line items

In millions of $ except per-share values · columns are period end dates